



Company Overview

JanOne (NASDAQ: JAN) is focused on developing treatments for diseases that cause severe pain. By alleviating pain at the source, JanOne aims to reduce the need for opioid prescriptions to treat disease associated pain that can lead to opioid abuse. The company is also exploring solutions for non-addictive pain medications. Its lead candidate JAN101 is for treating peripheral artery disease ("PAD"), a condition that affects over 8.5 million Americans. JAN101 demonstrated positive results in a Phase 2a clinical trial, and Phase 2b trials are expected to begin in early 2021. JanOne is dedicated to funding resources toward innovation, technology, and education for PAD, associated vascular conditions and neuropathic pain. JanOne continues to operate its legacy businesses under their current brand names, which are undergoing review to determine appropriate strategic alternatives.

JanOne Encouraged By Recent FDA Communications Regarding Phase 2B Clinical Trial Design of Lead Drug Candidate JAN101

Sep 28 2021, 4:05 PM EDT

JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients

Jul 22 2021, 9:45 AM EDT

JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites

Jun 23 2021, 10:10 AM EDT

Management Team

Tony Isaac

Chief Executive Officer and Director

Tony Giordano, Ph.D.

Chief Scientific Officer

Virland A. Johnson

Chief Financial Officer

Amol Soin, MD

Chief Medical Officer

JanOne Inc.

325 E. Warm Springs Road
Suite 102
Las Vegas, NV 89119

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.